<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201276</url>
  </required_header>
  <id_info>
    <org_study_id>glucosaminexzh</org_study_id>
    <nct_id>NCT03201276</nct_id>
  </id_info>
  <brief_title>Individual Differences in Glucosamine Sulfate Exposure Levels</brief_title>
  <official_title>Individual Differences in Glucosamine Sulfate Exposure Levels and Related Gene Polymorphism Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucosamine is an important part of the treatment strategy for osteoarthritis, but its
      effectiveness is still controversial. To explain the efficacy differences of glucosamine, in
      this study the investigators detect the concentration of glucosamine in the plasma and
      synovial fluid, some effect indexes such as inflammatory markers and gene polymorphism of
      glucosamine transporters. On the one hand, the investigators compare the plasma peak and
      gluten glucosamine concentration and the concentration in synovial fluid among participants
      to observe the individual differences of glucosamine exposure in vivo. On the other hand, the
      investigators investigate the correlation between drug concentrations, effect index and gene
      polymorphism. The hypothesis is that glucosamine exposure in vivo has individual differences
      and gene polymorphism can explain this differences.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Drug concentration in plasma</measure>
    <time_frame>Fasting venous blood before the first administration</time_frame>
    <description>Drug concentration is measured by HPLC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration in plasma</measure>
    <time_frame>3 hours after the third administration</time_frame>
    <description>Drug concentration is measured by HPLC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration in plasma</measure>
    <time_frame>9 hours after the third administration</time_frame>
    <description>Drug concentration is measured by HPLC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration in plasma</measure>
    <time_frame>Fasting venous blood before the fourth administration</time_frame>
    <description>Drug concentration is measured by HPLC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration in plasma</measure>
    <time_frame>Venous blood during the operation of total knee arthroplasty</time_frame>
    <description>Drug concentration is measured by HPLC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug concentration in synovial fluid</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>Drug concentration is measured by HPLC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the first administration</time_frame>
    <description>Leptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>3 hours after the third administration</time_frame>
    <description>Leptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>9 hours after the third administration</time_frame>
    <description>Leptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the fourth administration</time_frame>
    <description>Leptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>Leptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the first administration</time_frame>
    <description>IL-1β</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>3 hours after the third administration</time_frame>
    <description>IL-1β</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>9 hours after the third administration</time_frame>
    <description>IL-1β</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the fourth administration</time_frame>
    <description>IL-1β</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>IL-1β</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the first administration</time_frame>
    <description>COX-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>3 hours after the third administration</time_frame>
    <description>COX-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>9 hours after the third administration</time_frame>
    <description>COX-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the fourth administration</time_frame>
    <description>COX-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>COX-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the first administration</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>3 hours after the third administration</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>9 hours after the third administration</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the fourth administration</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the first administration</time_frame>
    <description>TNFα</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>3 hours after the third administration</time_frame>
    <description>TNFα</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>9 hours after the third administration</time_frame>
    <description>TNFα</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the fourth administration</time_frame>
    <description>TNFα</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>TNFα</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the first administration</time_frame>
    <description>MMP-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>3 hours after the third administration</time_frame>
    <description>MMP-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>9 hours after the third administration</time_frame>
    <description>MMP-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the fourth administration</time_frame>
    <description>MMP-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>MMP-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the first administration</time_frame>
    <description>ADAM-TS5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>3 hours after the third administration</time_frame>
    <description>ADAM-TS5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>9 hours after the third administration</time_frame>
    <description>ADAM-TS5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>Fasting venous blood before the fourth administration</time_frame>
    <description>ADAM-TS5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in plasma</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>ADAM-TS5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in synovial fluid</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>Leptin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in synovial fluid</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>IL-1β</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in synovial fluid</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>COX-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in synovial fluid</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in synovial fluid</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>TNFα</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in synovial fluid</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>MMP-3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers in synovial fluid</measure>
    <time_frame>During the operation of total knee arthroplasty</time_frame>
    <description>ADAM-TS5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene polymorphism</measure>
    <time_frame>Fasting venous blood before the first administration</time_frame>
    <description>Gene polymorphisms of glucosamine transporters in vivo</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Drug group</arm_group_label>
    <description>patients taking glucosamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine Sulfate</intervention_name>
    <description>Patients taking glucosamine sulfate 1500mg every day for at least four days.</description>
    <arm_group_label>Drug group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing total knee arthroplasty for knee osteoarthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients undergoing total knee arthroplasty for knee osteoarthritis;

          2. 60-80 years.

        Exclusion Criteria:

          1. patients with severe liver or renal insufficiency;

          2. patients allergic to glucosamine or any excipients in tablets;

          3. patients who have been treated with glucosamine within three months;

          4. patients who are unable to cooperate with the study;

          5. continuous medication is less than 4 days;

          6. patients with diarrhea, vomiting and other adverse reactions during medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qing Jiang</last_name>
    <phone>+8613605192953</phone>
    <email>qingj@nju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruijuan Xu</last_name>
    <phone>+8613851502360</phone>
    <email>jean0129@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Chan PS, Caron JP, Orth MW. Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. Am J Vet Res. 2007 Jul;68(7):709-15.</citation>
    <PMID>17605605</PMID>
  </reference>
  <reference>
    <citation>Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martín-Mola E, Paulino J, Marenco JL, Porto A, Laffon A, Araújo D, Figueroa M, Branco J. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum. 2007 Feb;56(2):555-67.</citation>
    <PMID>17265490</PMID>
  </reference>
  <reference>
    <citation>Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001 Sep;51(9):699-725. Review.</citation>
    <PMID>11642003</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Qing Jiang</investigator_full_name>
    <investigator_title>Vice Dean</investigator_title>
  </responsible_party>
  <keyword>glucosamine sulfate</keyword>
  <keyword>individual differences</keyword>
  <keyword>gene polymorphism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

